Caribou Biosciences
Caribou Biosciences raises $304M Series C at $1.2B valuation
Caribou Biosciences: Series C Funding Round
Caribou Biosciences has successfully raised $304M in Series C funding, reaching a valuation of $1.2B.
Company Overview
CRISPR gene editing for cell therapies
Funding Details
The Series C round was led by RA Capital Management, with participation from Baillie Gifford, Redmile Group, Pfizer Ventures.
Company Information
- Headquarters: 2929 Seventh Street, Berkeley, CA 94710
- Founded: 2011
- Employees: 200+
- Category: Biotech
Investment
Caribou Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital Management: Verified investor in Series C
- Baillie Gifford: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Pfizer Ventures: Verified investor in Series C
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free